GIBCO GRL, Random Primers DNA Labeling System, GIBCO BRL Catalogue and Reference Guide, Life Technologies, Inc. Gaithersburg, MD 20877, USA, p. 404. 1990.* |
Watson et al., Recombinant DNA, Chapter 5, pp. 63-77, Scientific American Books, 1994.* |
Geneseq, Acc. No. AAT23436, Aug. 16, 1996.* |
GenBank Acc. No. U97694, Aug. 27, 1997.* |
Hovig, E. et al., “CA 125: The End of the Beginning,” Tumor Biology 22: 345-347, 2001. |
O'Brien, T.J. et al., “The CA 125 Gene: A Newly Discovered Extension of the Glycosylated N-Terminal Domain Doubles the Size of This Extracellular Superstructure,” Tumor Biology 23: 154-169, 2002. |
O'Brien, T.J. et al., “The CA 125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences,” Tumor Biology 22: 348-366, 2001. |
Schummer, M. et al., “Comparative hybridization of an array of 21 500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas,” Gene 238: 375-385, 1999. |
Whitehouse, C. et al., “NBR1 interacts with fasciculation and elongation protein zeta-1 (FEZ1) and calcium and integrin binding protein (CIB) and shows developmentally restricted expression in the neural tube,” Eur. J. Biochem. 269: 538-545, 2002. |
Yin and Lloyd, “Molecular Cloning of the CA125 Ovarian Cancer Antigen. Identification as a new mucin, MUC16,” Journal of Biological Chemistry 276(29): 27371-27375, Jul. 20, 2001. |
Yin, B.W.T. et al., “Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene,” International Journal of Cancer 98: 737-740, 2002. |
Bookman et al., “Biological therapy of ovarian cancer: Current directions,” Seminars in Oncology, 25(3):381-396. |
Gillespie et al., “Mage, Bage and Gage: Tumour antigen expression in benign and malignant ovarian tissue,” British Journal of Cancer, 78(6):816-821, Sep., 1998. |
Heller et al., “Discovery and analysis of inflammatory disease-related genes using cDNA microarrays,” Proc. Natl. Acad. Sci. USA 94:2150-2155, Mar., 1997. |
Ishikawa et al., “Prediction of the coding sequence of unidentified human genes. The complete sequence of 100 new cDNA clones from brain which can code for large proteins i vitro,” DNA Res., 5:169-176, 1998. |
Jin et al., “Human T cell leukemia virus type 1 oncoprotein tax targets the human mitotic checkpoint protein MAD1,” Cell 93:81-91, Apr. 3, 1998. |
Köhler et al., “Immotherapy of Ovarian Carcinoma with the Monoclonal Anti-Idiotype Antibody ACA125—Results of the Phase LB Study,” Gebrutshilfe und Fraenheilkunde, 58(4):180-186, Apr. 1998 + (English Abstract). |
Ma et al., “Use of encapsulated single chain antibodies for induction of anti-idiotypic humoral and cellular immune responses,” Journal of Pharmaceutical Sciences, 87(11):1375 1378, Nov., 1998. |
Parker et al., “Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains,” The Journal of Immunology 152(1):163-175, Jan. 1, 1994. |
Peoples et al., “Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides,” Annals of Surgical Oncology, 5(8):743-750, Dec., 1998. |
Schena et al., “Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes,” Proc. Natl. Acad. Sci., 93:10614-10619, Oct., 1996. |